- Why the Extended Timeline Stands Out
- Why The Company Changed Terms
- Subscription
- GMP
- Updated Valuation
- What Investors Should Watch Now
Innovision IPO has been extended till March 17, 2026, and the company has also reduced its price band to ₹494-₹519 per share from the earlier ₹521-₹548. The move came after the issue saw weak demand in the first three days of bidding.
This update matters more than the usual IPO timeline change. When a company extends the issue and also cuts the asking price, it usually means investors were not fully comfortable with the original valuation or near-term risk-reward.
In this blog, we will focus on what has changed now: the revised dates, the new price band, today’s GMP, the latest subscription numbers available, and how the valuation looks after the price cut.
IPO Update
- IPO Open Date: March 10, 2026
- Old Closing Date: March 12, 2026
- New Closing Date: March 17, 2026
- Old Price Band: ₹521 to ₹548 per share
- New Price Band: ₹494 to ₹519 per share
The revised price band became effective from March 13, 2026. So from here on, the market will judge the IPO at this lower valuation, not the earlier one.
Why the Extended Timeline Stands Out
One more thing stands out here: the IPO will now remain open for 6 working days, which is longer than what investors usually see in a mainboard IPO. As per SEBI, book-built public issues normally stay open for 3 to 7 working days. If the price band is revised during the issue, the bidding period has to be extended by 3 more working days, subject to the total issue period not going beyond 10 working days. Since Innovision has changed its price band, this longer window is unusual, but still fully within the rules.
Why The Company Changed Terms
The simple reason is weak demand in the first round of bidding. By the end of March 12, the IPO had been subscribed only 32% overall.
This was a weak response, not just a slow one. With overall subscription at only 32%, the IPO was still far below the 90% minimum subscription level usually needed for listing, so the extension and price cut look like a clear attempt to revive demand.
For detailed information, visit Innovision’s official IPO page at INDmoney.
Subscription
As of 11:30 AM, March 13, 2026, the Innovision IPO was subscribed 30% overall. The QIB portion was subscribed 95%, the NII portion 35%, and the retail portion 27%.
This split tells an interesting story. Institutional demand was close to fully covered, but retail demand remained weak, which suggests smaller investors were not fully convinced at the earlier price band.
GMP
As of today, GMP signals remain flat to weak. The GMP is around ₹2, which means the market is pricing only 0.39% listing gain at the revised upper price band.
That is important because GMP, or grey market premium, is an unofficial signal of listing sentiment. It is not reliable enough to base an investment decision on, but when GMP stays flat even after a price cut, it usually tells you enthusiasm is still limited.
Updated Valuation
At the revised upper price band of ₹519, Innovision’s post-IPO market capitalisation now works out to about ₹1,222 crore, while the P/E ratio comes down to 30.55x. This is lower than the earlier valuation of roughly ₹1,291 crore market cap and 32.26x P/E at ₹548 per share.
In simple words, the stock is a little cheaper now than it was earlier, but it is still not exactly cheap. Even after the cut, investors are still paying more than 30 times earnings, which is a premium valuation for a services business with thin margins and meaningful client concentration risk.
The broader logic from the earlier valuation still mostly holds. The fresh issue can still help the company improve its balance sheet and fund working capital needs, which is important for a business that has to pay salaries, place deposits, and provide bank guarantees upfront. At the same time, the main concerns have not disappeared: Innovision still operates in a low-margin business, still depends heavily on NHAI for revenue, and still needs to show that growth can stay strong without stretching cash flows too much.
Check the detailed Innovision IPO review here.
What Investors Should Watch Now
The next few days matter more than the first three. Investors should track whether the lower price band improves retail participation and whether overall subscription moves meaningfully closer to full coverage before March 17.
More importantly, the conversation has now shifted from “Is this a good growth story?” to “Is the revised valuation fair enough for the risks?” That is the real question after this extension and price cut, and it is what should shape investor interest from here.
For a seamless application process, visit the INDmoney IPO page.
Disclaimer
Source: Innovision's RHP. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Please be informed that merely opening a trading and demat account will not guarantee investment in securities in the IPO. Investors are requested to do their own independent research and due diligence before investing in an IPO. Please read the SEBI-prescribed Combined Risk Disclosure Document prior to investing. This post is for general information and awareness purposes only and is nowhere to be considered as advice, recommendation, or solicitation of an offer to buy or sell, or subscribe for securities. INDstocks is acting as a distributor for non-broking products/services such as IPO, Mutual Fund, and Mutual Fund SIP. These are not exchange-traded products. All disputes with respect to the distribution activity would not have access to the Exchange investor redressal forum or the Arbitration mechanism. INDstocks Private Limited (formerly known as INDmoney Private Limited) does not provide any portfolio management services, nor is it an investment adviser. Logos above are the property of respective trademark owners, and by displaying them, INDstocks has no right, title, or interest in them. SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428.